Perifosine News and Research

RSS
Perifosine is a substance that is being studied in the treatment of cancer. Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.
Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting

Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Aeterna Zentaris raises $13.7M through registered direct offering

Aeterna Zentaris raises $13.7M through registered direct offering

MicroStockProfit.com releases investment report on AEterna Zentaris

MicroStockProfit.com releases investment report on AEterna Zentaris

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster obtains first Ethics Committee approval for CLARITY study

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

Health care reform will have negative effect on cardiology patients, practices: American cardiologists

Health care reform will have negative effect on cardiology patients, practices: American cardiologists